Zobrazeno 1 - 10
of 254
pro vyhledávání: '"Richard W Joseph"'
Autor:
Brian I. Rini, Dena Battle, Robert A. Figlin, Daniel J. George, Hans Hammers, Tom Hutson, Eric Jonasch, Richard W. Joseph, David F. McDermott, Robert J. Motzer, Sumanta K. Pal, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-20 (2019)
Abstract The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune che
Externí odkaz:
https://doaj.org/article/eee5402a5743458ab14e581acfdc6861
Autor:
Patricia M LoRusso, Aleksandar Sekulic, Jeffrey A Sosman, Winnie S Liang, John Carpten, David W Craig, David B Solit, Alan H Bryce, Jeffrey A Kiefer, Jessica Aldrich, Sara Nasser, Rebecca Halperin, Sara A Byron, Mary Jo Pilat, Scott A Boerner, Diane Durecki, William P D Hendricks, Daniel Enriquez, Tyler Izatt, Jonathan Keats, Christophe Legendre, Svetomir N Markovic, Amy Weise, Fatima Naveed, Jessica Schmidt, Gargi D Basu, Shobana Sekar, Jonathan Adkins, Erica Tassone, Karthigayini Sivaprakasam, Victoria Zismann, Valerie S Calvert, Emanuel F Petricoin, Leslie Anne Fecher, Christopher Lao, J Paul Eder, Nicholas J Vogelzang, Jane Perlmutter, Mark Gorman, Barbara Manica, Lisa Fox, Nicholas Schork, Daniel Zelterman, Michelle DeVeaux, Richard W Joseph, C Lance Cowey, Jeffrey M Trent
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0248097 (2021)
Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAFV600 mutations, targeted agents have been ineffective for BRAFV600wild-type (wt) metastatic melanomas. The SU2C Genomics-
Externí odkaz:
https://doaj.org/article/ea286e5ad5d3466fb04534c8639561db
Autor:
Thomas T DeLeon, Daniel R Almquist, Benjamin R Kipp, Blake T Langlais, Aaron Mangold, Jennifer L Winters, Heidi E Kosiorek, Richard W Joseph, Roxana S Dronca, Matthew S Block, Robert R McWilliams, Lisa A Kottschade, Kandelaria M Rumilla, Jesse S Voss, Mahesh Seetharam, Aleksandar Sekulic, Svetomir N Markovic, Alan H Bryce
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0230306 (2020)
BACKGROUND:CDKN2A and TP53 mutations are recurrent events in melanoma, occurring in 13.3% and 15.1% of cases respectively and are associated with poorer outcomes. It is unclear what effect CDKN2A and TP53 mutations have on the clinical outcomes of pa
Externí odkaz:
https://doaj.org/article/3927fd1a2b3d44719753600a2b2972b4
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-9 (2018)
Nivolumab, a monoclonal antibody against programmed cell death-1 receptor, is increasingly used in advanced cancers. While nivolumab use enhances cancer therapy, it is associated with increased immune-related adverse events. We describe an elderly ma
Externí odkaz:
https://doaj.org/article/8112aa1ed1d240bf9e094ac11f2fdbef
Autor:
Elizabeth I. Buchbinder, Douglas B. Johnson, Jeffrey A. Sosman, F. Stephen Hodi, Patrick A. Ott, Rizwan Haq, Richard W. Joseph, Jason J. Luke, Fei Ye, Shilin Zhao, Paul D. Leger, Alpaslan Ozgun, Zeynep Eroglu, Daniel Y. Wang
Supplementary Figure 1: Post-progresion survival based on initial PFS (6, 9, 12, and 15 months). Supplementary Figure 2: Radiographic example of isolated progression in one patient with acquired resistance to anti-PD-1. Supplementary Figure 3: Overal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06d5ddeec8aab0a8ede8668c437d3546
https://doi.org/10.1158/2326-6066.22537699
https://doi.org/10.1158/2326-6066.22537699
Autor:
Thai H. Ho, Erik P. Castle, Melissa L. Stanton, Nicholas J. Vogelzang, Alan H. Bryce, Sandeep Reddy, Zoran Gatalica, David Bryant, Estrella M. Carballido, Sherri Z. Millis, Richard W. Joseph
Monoclonal antibodies that target the programmed death-1 (PD-1)–programmed death ligand-1 (PD-L1) axis have antitumor activity against multiple cancers. The presence of sarcomatoid differentiation in renal cell carcinoma (RCC) is associated with re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e514ab57d1af3f54a9b8792c50e68b2b
https://doi.org/10.1158/2326-6066.c.6548648.v1
https://doi.org/10.1158/2326-6066.c.6548648.v1
Autor:
Elizabeth I. Buchbinder, Douglas B. Johnson, Jeffrey A. Sosman, F. Stephen Hodi, Patrick A. Ott, Rizwan Haq, Richard W. Joseph, Jason J. Luke, Fei Ye, Shilin Zhao, Paul D. Leger, Alpaslan Ozgun, Zeynep Eroglu, Daniel Y. Wang
Anti–PD-1 therapy has improved clinical outcomes in advanced melanoma, but most patients experience intrinsic resistance. Responding patients can develop acquired resistance to anti–PD-1. We retrospectively reviewed 488 patients treated with anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::251a086e4cf2895e9bf889357fe3a90b
https://doi.org/10.1158/2326-6066.c.6548527.v1
https://doi.org/10.1158/2326-6066.c.6548527.v1
Autor:
Thai H. Ho, Erik P. Castle, Melissa L. Stanton, Nicholas J. Vogelzang, Alan H. Bryce, Sandeep Reddy, Zoran Gatalica, David Bryant, Estrella M. Carballido, Sherri Z. Millis, Richard W. Joseph
Supplemental Table. Concordance of Immunohistochemical Staining of PD-L1 Expression (130021 vs SP142 antibody) in 19 Renal Cell Carcinomas With Sarcomatoid Differentiation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03c940914c9e0b432861075ae3138d0d
https://doi.org/10.1158/2326-6066.22538045
https://doi.org/10.1158/2326-6066.22538045
Autor:
Gregory Lizée, Patrick Hwu, Jennifer A. Wargo, Michael A. Davies, Richard E. Davis, Laszlo G. Radvanyi, Elizabeth Grimm, Suhendan Ekmekcioglu, Chantale Bernatchez, Richard W. Joseph, Min Zhang, Yufeng Li, Dennie T. Frederick, Zachary A. Cooper, Minying Zhang, Chengwen Liu, Seth Wardell, Mayra Whittington, Tania G. Rodríguez-Cruz, Shujuan Liu, Jahan S. Khalili
PDF file, 212K, (A) H&E staining of representative, A375 human xenograft tumor sections excised from NOD/SCID mice. Prior to excision, mice with established tumors were treated for 3 days with either PLX4720 or DMSO vehicle control. Magnification: 4x
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72f77b8a82cddbbc65e1c3ffb71cfedb
https://doi.org/10.1158/1078-0432.22455612
https://doi.org/10.1158/1078-0432.22455612
Autor:
Tara C. Gangadhar, Keaven M. Anderson, Scot Ebbinghaus, S. Peter Kang, Jin Zhang, Andrea Perrone, Dinesh P. de Alwis, Amita Patnaik, Jeffrey S. Weber, Peter Hersey, Roxana Dronca, Adil Daud, Caroline Robert, Omid Hamid, F. Stephen Hodi, Antoni Ribas, Anthony M. Joshua, Jedd D. Wolchok, Wen-Jen Hwu, Richard Kefford, Jeroen Elassaiss-Schaap, Richard W. Joseph
Supplemental Table
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26176e6e3787608edb4bcad0a45a1799
https://doi.org/10.1158/1078-0432.22468532.v1
https://doi.org/10.1158/1078-0432.22468532.v1